Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Public-private partnership: from there to here.

Simon L Croft1

  • 1Drugs for Neglected Diseases Initiative (DNDi), 1 place Saint Gervais, 1201 Geneva, Switzerland. scroft@dndi.org

Transactions of the Royal Society of Tropical Medicine and Hygiene
|August 10, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The development of a global research agenda and individual participant data platform for visceral leishmaniasis: challenges and future opportunities.

Parasites & vectors·2025
Same author

Comparative <i>in vitro</i> susceptibility of clinical <i>Leishmania</i> isolates to miltefosine and oleylphosphocholine.

Frontiers in pharmacology·2025
Same author

Challenges in sustaining the elimination of visceral leishmaniasis in India.

International health·2025
Same author

Comparative assessment of macrophage responses and antileishmanial efficacy in dynamic vs. Static culture systems utilizing chitosan-based formulations.

PloS one·2025
Same author

Dermal microdialysis: A method to determine drug levels in the skin of patients with Post kala-azar dermal leishmaniasis (PKDL).

Experimental parasitology·2023
Same author

Efficacy of oleylphosphocholine in experimental cutaneous leishmaniasis.

The Journal of antimicrobial chemotherapy·2023

Public-private partnerships (PD PPPs) are accelerating drug discovery for tropical diseases. However, sustainable funding and equitable product delivery remain critical challenges for these vital initiatives.

Area of Science:

  • Drug Discovery and Development
  • Global Health
  • Pharmaceutical R&D

Background:

  • Rising drug development costs have led pharmaceutical companies to withdraw from researching treatments for tropical and neglected diseases.
  • Public-private partnerships (PD PPPs) have emerged as a response to this gap, focusing on diseases prevalent in developing nations.
  • These partnerships aim to address the translational research gap, connecting basic science with clinical application.

Purpose of the Study:

  • To examine the impact of PD PPPs on the discovery and development of new medicines for tropical and neglected diseases.
  • To identify key challenges and opportunities for PD PPPs in the current R&D landscape.
  • To explore strategies for enhancing the sustainability and effectiveness of these partnerships.

Main Methods:

Related Experiment Videos

  • Analysis of recent trends in research and development (R&D) for tropical and neglected diseases.
  • Evaluation of the role and structure of public-private partnerships in drug development.
  • Assessment of funding models, R&D timelines, and attrition rates within these partnerships.

Main Results:

  • PD PPPs have demonstrated efficiency in advancing compounds through the R&D pipeline.
  • A significant portion of funding currently relies on a small number of philanthropic organizations.
  • Drug development remains a lengthy process with a high rate of project failure (90% attrition).

Conclusions:

  • PD PPPs are crucial for developing treatments for neglected diseases, but require diversified and stable funding.
  • Ensuring equitable access to developed medicines and involving scientists from endemic countries are essential next steps.
  • Greater understanding of R&D attrition rates among funders is needed to secure long-term support for PD PPPs.